Loading...
Market
Will 4DMT's 4D-150 gene therapy for wet-AMD complete Phase 3 trials by June 30, 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
4DMT official announcements and clinical trial registries
Story
4D Molecular Announces Positive Results for 4D-150 Wet-AMD Gene Therapy
Sep 18, 2024, 08:08 PM
4D Molecular Therapeutics (4DMT) has announced positive results in the development of a gene therapy for wet age-related macular degeneration (wet-AMD), a leading cause of age-related blindness. The therapy, known as 4D-150, has shown robust and durable clinical activity. Notably, only two out of 71 dosed patients have exhibited signs of ocular inflammation. The company has also outlined the design for its upcoming Phase 3 program, known as 4FRONT, during the 4D-150 Wet AMD Development Day. This progress highlights the ongoing advancements in gene therapy, particularly in treatments for common conditions like wet-AMD.
View original story
Similar markets
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Less than 50% efficacy • 25%
50-69% efficacy • 25%
70-89% efficacy • 25%
90% or higher efficacy • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
